BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 30513220)

  • 21. Bortezomib-based induction for transplant ineligible AL amyloidosis and feasibility of later transplantation.
    Cornell RF; Zhong X; Arce-Lara C; Atallah E; Blust L; Drobyski WR; Fenske TS; Pasquini MC; Rizzo JD; Saber W; Hari PN
    Bone Marrow Transplant; 2015 Jul; 50(7):914-7. PubMed ID: 25915809
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Addition of cyclophosphamide and higher doses of dexamethasone do not improve outcomes of patients with AL amyloidosis treated with bortezomib.
    Kastritis E; Gavriatopoulou M; Roussou M; Fotiou D; Ziogas DC; Migkou M; Eleutherakis-Papaiakovou E; Panagiotidis I; Kanellias N; Psimenou E; Papadopoulou E; Pamboucas C; Manios E; Gakiopoulou H; Ntalianis A; Tasidou A; Giannouli S; Terpos E; Dimopoulos MA
    Blood Cancer J; 2017 Jun; 7(6):e570. PubMed ID: 28622303
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Haematologic responses and survival do not significantly decrease with subsequent lines of therapy in systemic immunoglobulin light chain amyloidosis: results from an analysis of real-world longitudinal data.
    Ravichandran S; Cohen OC; Law S; Sachchithanantham S; Mahmood S; Foard D; Fontana M; Martinez-Naharro A; Whelan C; Gillmore JD; Lachmann HJ; Hawkins PN; Wechalekar AD
    Br J Haematol; 2021 Aug; 194(3):587-597. PubMed ID: 34189728
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic significance of interventricular septal thickness in patients with AL amyloidosis.
    Cho H; Kim SJ; Shim CY; Hong GR; Ha JW; Kim YR; Yang WI; Chung H; Jang JE; Cheong JW; Min YH; Kim JS
    Leuk Res; 2017 Sep; 60():36-43. PubMed ID: 28648672
    [TBL] [Abstract][Full Text] [Related]  

  • 25. European Collaborative Study Defining Clinical Profile Outcomes and Novel Prognostic Criteria in Monoclonal Immunoglobulin M-Related Light Chain Amyloidosis.
    Sachchithanantham S; Roussel M; Palladini G; Klersy C; Mahmood S; Venner CP; Gibbs S; Gillmore J; Lachmann H; Hawkins PN; Jaccard A; Merlini G; Wechalekar AD
    J Clin Oncol; 2016 Jun; 34(17):2037-45. PubMed ID: 27114592
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Carfilzomib is an effective upfront treatment in AL amyloidosis patients with peripheral and autonomic neuropathy.
    Manwani R; Mahmood S; Sachchithanantham S; Lachmann HJ; Gillmore JD; Yong K; Rabin N; Popat R; Kyriakou C; Worthington S; Sharpley F; Smith M; Shah R; Cheesman S; Hawkins PN; Wechalekar AD
    Br J Haematol; 2019 Dec; 187(5):638-641. PubMed ID: 31388995
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neuropathy and efficacy of once weekly subcutaneous bortezomib in multiple myeloma and light chain (AL) amyloidosis.
    Sidana S; Narkhede M; Elson P; Hastings D; Faiman B; Valent J; Samaras C; Hamilton K; Liu HK; Smith MR; Reu FJ
    PLoS One; 2017; 12(3):e0172996. PubMed ID: 28278302
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictors of treatment response and survival outcomes in patients with advanced cardiac AL amyloidosis.
    Gustine JN; Staron A; Mendelson L; Joshi T; Gopal DM; Siddiqi OK; Ruberg FL; Sanchorawala V
    Blood Adv; 2023 Oct; 7(20):6080-6091. PubMed ID: 37581513
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bortezomib with dexamethasone as first-line treatment for AL amyloidosis with renal involvement.
    Huang X; Wang Q; Chen W; Ren G; Liu Z
    Amyloid; 2016; 23(1):51-7. PubMed ID: 26862817
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of the combination of bortezomib and dexamethasone in systemic AL amyloidosis.
    Lamm W; Willenbacher W; Lang A; Zojer N; Müldür E; Ludwig H; Schauer-Stalzer B; Zielinski CC; Drach J
    Ann Hematol; 2011 Feb; 90(2):201-6. PubMed ID: 20821326
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic value of left atrial function in systemic light-chain amyloidosis: a cardiac magnetic resonance study.
    Mohty D; Boulogne C; Magne J; Varroud-Vial N; Martin S; Ettaif H; Fadel BM; Bridoux F; Aboyans V; Damy T; Jaccard A
    Eur Heart J Cardiovasc Imaging; 2016 Sep; 17(9):961-9. PubMed ID: 27194782
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of Chemotherapy for Light-Chain Amyloidosis in Patients Presenting With Symptomatic Heart Failure.
    Sperry BW; Ikram A; Hachamovitch R; Valent J; Vranian MN; Phelan D; Hanna M
    J Am Coll Cardiol; 2016 Jun; 67(25):2941-8. PubMed ID: 27339491
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence and prognostic impact of left-sided valve thickening in systemic light-chain amyloidosis.
    Mohty D; Pradel S; Magne J; Fadel B; Boulogne C; Petitalot V; Raboukhi S; Darodes N; Damy T; Aboyans V; Jaccard A
    Clin Res Cardiol; 2017 May; 106(5):331-340. PubMed ID: 27933393
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains.
    Sidana S; Tandon N; Dispenzieri A; Gertz MA; Buadi FK; Lacy MQ; Dingli D; Fonder AL; Hayman SR; Hobbs MA; Gonsalves WI; Hwa YL; Kapoor P; Kyle RA; Leung N; Go RS; Lust JA; Russell SJ; Zeldenrust SR; Rajkumar SV; Kumar SK
    Leukemia; 2018 Mar; 32(3):729-735. PubMed ID: 28919633
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens.
    Bochtler T; Hegenbart U; Kunz C; Granzow M; Benner A; Seckinger A; Kimmich C; Goldschmidt H; Ho AD; Hose D; Jauch A; Schönland SO
    J Clin Oncol; 2015 Apr; 33(12):1371-8. PubMed ID: 25779559
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Treatment of systemic AL amyloidosis: about 25 cases].
    Eddou H; Zinebi A; Maaroufi HE; Moudden MK; Doghmi K; Mikdame M; Baaj ME
    Pan Afr Med J; 2017; 28():160. PubMed ID: 29541306
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increased Prognostic Value of Query Amyloid Late Enhancement Score in Light-Chain Cardiac Amyloidosis.
    Wan K; Sun J; Han Y; Liu H; Yang D; Li W; Wang J; Cheng W; Zhang Q; Zeng Z; Chen Y
    Circ J; 2018 Feb; 82(3):739-746. PubMed ID: 29093431
    [TBL] [Abstract][Full Text] [Related]  

  • 38.  Liver transplantation followed by autologous stem cell transplantation for acute liver failure caused by AL amyloidosis. Case report and review of the literature.
    Elnegouly M; Specht K; Zoller H; Matevossian E; Bassermann F; Umgelter A
    Ann Hepatol; 2016; 15(4):592-7. PubMed ID: 27236160
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plasma cell proliferative index predicts outcome in immunoglobulin light chain amyloidosis treated with stem cell transplantation.
    Sidiqi MH; Aljama MA; Jevremovic D; Morice WG; Timm M; Buadi FK; Warsame R; Lacy MQ; Dispenzieri A; Dingli D; Gonsalves WI; Kumar S; Kapoor P; Kourelis T; Leung N; Hogan WJ; Gertz M
    Haematologica; 2018 Jul; 103(7):1229-1234. PubMed ID: 29674497
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ten-year survivors in AL amyloidosis: characteristics and treatment pattern.
    Muchtar E; Gertz MA; Lacy MQ; Go RS; Buadi FK; Dingli D; Grogan M; AbouEzzeddine OF; Hayman SR; Kapoor P; Leung N; Fonder A; Hobbs M; Hwa YL; Gonsalves W; Warsame R; Kourelis TV; Russell S; Lust JA; Lin Y; Zeldenrust S; Kyle RA; Rajkumar SV; Kumar SK; Dispenzieri A
    Br J Haematol; 2019 Dec; 187(5):588-594. PubMed ID: 31298751
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.